REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
methylPREDNISolone

Effective Date: Dec 2012 **Revised Date:** Sept 16 2020 **Reviewed Date:**	CLASSIFICATION **Steroid**	OTHER NAMES **Solu-Medrol**	PAGE 1 of 2

ADMINISTRATION POLICY:

IV Bolus - May be administered by a nurse
IV Intermittent - May be administered by a nurse
IM - Not recommended
Subcut - Avoid (may result in dermal or subdermal atrophy)

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as:

Sterile powder vials:

Vial Size	Diluent Volume (Sterile Water for Injection)	Final Volume	Final Concentration
40 mg	1 mL	1 mL	40 mg/mL
125 mg	2 mL	2 mL	62.5 mg/mL
500 mg	7.8 mL	8 mL	62.5 mg/mL
1 gram	15.6 mL	16 mL	62.5 mg/mL

OR

Act-O-Vial System:

- Mix the medication vial by pressing down on the top of the vial to release the cork and force diluents into the lower compartment
- Shake the vial to mix the medication solution well
- Remove the plastic tab covering the center of the stopper
- Sterilize the top of vial
- Insert the needle through the center of the stopper, invert the vial and withdraw the appropriate dose

Act-O-Vial Size	Volume of Diluent to be added	Final Concentration
40 mg	Entire contents supplied	40 mg/mL
125 mg	Entire contents supplied	62.5 mg/mL
500 mg	Entire contents supplied	125 mg/mL
1 g	Entire contents supplied	125 mg/mL

IV Bolus: Restricted to doses less than 250 mg. Reconstitute vial as above and administer undiluted over 3 to 5 minutes.

IV Intermittent: For doses less than 250 mg: After reconstitute, dilute further in 50 mL normal saline and administer over 15 to 30 minutes
For doses equal to or greater than 250 mg: After reconstitution, dilute further in at least 100 mL normal saline and administer over at least 30 minutes

Maximum rate: Doses less than 250 mg: over 3 minutes (IV Bolus)
Doses equal to or greater than 250 mg: over 30 minutes (IV Intermittent)
30 mg/kg over 15 minutes (spinal cord injury)

Maximum concentration: 62.5 mg/mL (IV Bolus)

REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
methylPREDNISolone

Effective Date: Dec 2012 **Revised Date:** Sept 16 2020 **Reviewed Date:**	CLASSIFICATION **Steroid**	OTHER NAMES **Solu-Medrol**	PAGE 2 of 2

DOSAGE:
Usual:
Acute exacerbation of Multiple Sclerosis: 1 gram IV daily 3-7 days

Other disorders:	40 to 250 mg every 6 hours (doses are highly variable, based on indication)
Spinal Cord Injury:	IV Bolus: 30 mg/kg over 15 minutes
Maximum single dose:	30 mg/kg

STABILITY/COMPATIBILITY:

Stability of Reconstituted Solution:	24 hours at room temperature
Stability of Final Admixture:	24 hours at room temperature
Compatibility:	Compatible with normal saline, D5W and dextrose-saline combinations.

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Cardiovascular collapse may occur with too rapid injection of doses greater than 250 mg
- Long term therapy predisposes to sodium retention, edema and reduced resistance to infection, peptic ulcer, and increase in blood glucose.
- Health Canada is alerting that severe hypersensitivity reactions in patients hypersensitive to milk following the use of Pfizer Canada's SOLU-MEDROL ACT-O-VIAL (methylprednisolone sodium succinate for injection) 40 mg have been internationally reported in the postmarketing setting. SOLU-MEDROL ACT-O-VIAL 40 mg, the only SOLU-MEDROL formulation available in Canada containing bovine-sourced lactose as an excipient, is contraindicated in patients with a known or suspected hypersensitivity to cow's milk. Alternative treatments, including corticosteroid formulations that do not contain bovine-sourced ingredients, should be considered for acute allergy management in patients allergic to cow's milk proteins due to the potential for SOLU-MEDROL ACT-O-VIAL 40 mg to exacerbate the condition.
- Do not confuse methylprednisolone acetate (Depo-Medrol) which is for **IM USE ONLY,** with methylprednisolone sodium succintate (Solu-Medrol).